Q-omics provides the consensus-scored ZNF543 profile across patient tissues and cancer cell-line models. ZNF543 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF543 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, ZNF543 RNA expression shows 21,607 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LIHC, and ACC as cancer lineages where ZNF543 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF543 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF543 survival associations across molecular data types. ZNF543 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF543 RNA expression–survival associations across cancer types. High ZNF543 expression shows unfavorable associations in MESO, LGG and ACC, but favorable associations in KIRC, SCLC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF543 RNA expression.
This table summarizes ZNF543 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF543. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF543 shows lower tumor expression in THCA and higher tumor expression in LIHC, CHOL, LUSC, HNSC and BLCA. The LIHC box plot shows higher ZNF543 RNA expression in tumor versus normal tissue (log2 FC = +0.722, t-test p < 0.001).
This table shows molecular features associated with ZNF543 in patient tissues and cancer cell lines. In patient samples, ZNF543 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF543 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
